Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of C$0.09 and traded as low as C$0.09. Hemostemix shares last traded at C$0.09, with a volume of 2,000 shares changing hands.
Hemostemix Price Performance
The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The company’s 50-day simple moving average is C$0.09 and its 200-day simple moving average is C$0.09. The stock has a market capitalization of C$16.02 million, a P/E ratio of -3.15 and a beta of 0.80.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Featured Stories
- Five stocks we like better than Hemostemix
- Your Bank Account Is No Longer Safe
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- New gold price target
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
